Explore a selection of our essential drug information below, or:
Identification
- Summary
Crotalus scutulatus antivenin is a mixture of antibodies used to treat venomous snake bites from Crotalus scutulatus (Mojave rattlesnake).
- Brand Names
- Crofab
- Generic Name
- Crotalus scutulatus antivenin
- DrugBank Accession Number
- DB13891
- Background
Crotalus scutulatus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus scutulatus (also known as the Mojave rattlesnake 2).
The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. It is intravenously administered to limit systemic toxicity Label, 3, 4.
CROFAB (crotalidae polyvalent immune fab (ovine))is a sheep-derived antivenin used for the management of adult and pediatric patients with North American crotalid envenomation Label, which includes the Crotalus scutulatus snake (Mojave snake).
Mojave rattlesnakes inhabit desert areas of the southwestern United States and central Mexico. Specimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico 2.
Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. CroFab is more specifically tailored for crotalids of North America and is less allergenic than whole immunoglobulin antivenoms 7.
- Type
- Biotech
- Groups
- Approved, Experimental
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Crotalus scutulatus immune fab antivenin (ovine)
Pharmacology
- Indication
CROFAB is indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Reversal of Venom poisoning caused by crotalus scutulatus •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Acts as an antivenin, relieving symptoms of envenomation from Crotalinae family of snakes, and preventing lethal consequences of snake evenomation Label.
The Crotalidae family produces venoms which are generally necrolytic and hemolyzing to tissues. Hemorrhagins in crotalid venom is toxic to the blood vessels and therefore cause hemorrhage and edema at the wound site, in addition to systemic hemorrhage and shock. Significant anemia is observed due to hemolysis and extravasation of blood due to damaged vessels. Disseminated intravascular coagulation (DIC) has been observed in some cases. The most frequent initial clinical pathological changes include echinocytosis, thrombocytopenia, leukocytosis and prolonged activated clotting time. In general, edema and erythema along with fang marks (_Crotalidae _family) may be seen at the site of bite although it is tough to identify due to thick hair coat in animals 8.
Patients sustaining rattlesnake envenomation often develop thrombocytopenia, the etiology of which is not clear. It has been shown thatCrotaline Fab antivenom improved platelet aggregation in an in vitro model of platelet dysfunction induced by venom from C. scutulatus 1.
- Mechanism of action
CROFAB is a venom-specific Fab fragment of immunoglobulin G (IgG) that works by binding and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body Label
- Absorption
Not Available
- Volume of distribution
0.3 L/kg Label
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Approximately 15 hours Label
- Clearance
32 mL/min (approximately 0.4 mL/min/kg) Label
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Ed50 for the Crotolus scutulatus snake evenomation is 8 mg antivenin/mg venom Label.
Most common adverse reactions (incidence ≥5% of subjects) were urticaria, rash nausea, pruritus and back pain. Hypersensitivity reactions may also occur Label.
Hypersensitivity reactions can occur to substances derived from sheep plasma; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to sheep protein. Immediate treatment (including epinephrine 1 mg/mL) for anaphylaxis and/or hypersensitivity reactions must be available prior to administration. In cases of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Sensitization may occur with repeated doses of antivenin 5.
Drugs, such as crotalidae antivenin which are processed with papain, may lead to hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross-allergenicity with dust mite and latex allergens 5.
Late serum reactions (rash, pruritus, urticaria, or serum sickness consisting of severe rash and pruritus) reported in 12% (5/42) of patients in initial clinical trials have been observed and delayed hypersensitivity or serum sickness reported in 5–11% of patients in other studies 5.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CroFab Crotalus scutulatus antivenin (1 g/1) + Agkistrodon piscivorus antivenin (1 g/1) + Crotalus adamanteus antivenin (1 g/1) + Crotalus atrox antivenin (1 g/1) Injection, powder, lyophilized, for solution Intravenous BTG International Inc. 2000-02-10 Not applicable US 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans
Chemical Identifiers
- UNII
- 7WZ1744G86
- CAS number
- Not Available
References
- General References
- Carstairs SD, Kreshak AA, Tanen DA: Crotaline Fab antivenom reverses platelet dysfunction induced by Crotalus scutulatus venom: an in vitro study. Acad Emerg Med. 2013 May;20(5):522-5. doi: 10.1111/acem.12135. [Article]
- Mojave Rattlesnake Envenomation [Link]
- Crotalidae Polyvalent Immune Fab [Link]
- Crofab.com [Link]
- Drugs.com Crotalidae polyvalent immune fab [Link]
- Mayo clinic: Antivenin (crotalidae) [Link]
- Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations [Link]
- Review of Agkistrodon-Piscivorus [Link]
- External Links
- FDA label
- Download (407 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Snake Bite 1 somestatus stop reason just information to hide 4 Terminated Treatment Snake Envenomation 1 somestatus stop reason just information to hide 3 Completed Treatment Snake Bite 1 somestatus stop reason just information to hide 2 Completed Treatment Coagulation Disorder / Snake Bite 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 08, 2017 20:22 / Updated at June 19, 2021 00:27